Johnson & Johnson to Participate in the Cantor Virtual Global Healthcare Conference
New Brunswick, N.J., August 26, 2021 -- Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on Tuesday, September 28th. Mathai Mammen, Global Head, Research & Development Janssen Research Development and Scott White, Company Group Chairman NA Pharmaceuticals will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hrs after the live webcast. ### (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design
New Brunswick, N.J. – August 26, 2021 – Johnson & Johnson (NYSE: JNJ) today announced it is accepting applications for its 2022 Women in STEM2D (WiSTEM2D) Scholars Award. The award, which aims to support assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design, provides recipients with three years of mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is September 27, 2021 at 9 a.m. HST, and guidelines and additional details are available here: https://www.jnj.com/wistem2d-un...
Source: Johnson and Johnson - August 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

DePuy Synthes to Showcase Innovation Momentum at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Raynham, Mass., Aug. 25, 2021 -- The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes,** The Orthopaedics Company of Johnson & Johnson, will feature new products and technology solutions shaping new standards of care for modern day orthopaedics during the American Academy of Orthopaedic Surgeons (AAOS) annual meeting Aug. 31–Sept. 3 in San Diego. From robotics and more personalized implants to connected instrumentation, advanced imaging and visualization technology, DePuy Synthes will showcase next generation product innovations spanning its VELYS™ Digital Surgery, Hip, Knee, Shoulder, ...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine. In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization. In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals pre...
Source: Johnson and Johnson - August 25, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022
New Brunswick, N.J. (August 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced that Mr. Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. Following the transition of the Chief Executive Officer role, Mr. Duato will also be appointed as a member of the Company’s Board of Directors. “It has been an honor and privilege to lead this company as Chairman and CEO for nearly a decade, and...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).[1] These findings will be featured at th...
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine
NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.In July, Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least e...
Source: Johnson and Johnson - August 18, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

DePuy Synthes Introduces the INHANCE ™ Shoulder System, a First-to-Market, Fully Integrated Shoulder Arthroplasty System
RAYNHAM, MA – August 18, 2021 – Today, The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson,** introduces the INHANCE™ Shoulder System, a first-to-market, fully integrated shoulder arthroplasty system. The system is designed with an intuitive stemless-first surgical approach that aligns with how surgeons approach patient care. The INHANCE Shoulder System is the first shoulder system to offer surgeons the ability to seamlessly transition from stemless to stemmed implants during surgical procedures. There are many reasons surgeons may need ...
Source: Johnson and Johnson - August 18, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
New Brunswick, NJ (August 12, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15th. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Mathai Mammen, Global Head, Research & Development Janssen Research Development will represent the Company in a session scheduled at 9:30 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hrs after the l...
Source: Johnson and Johnson - August 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ethicon ’s Echelon Circular Powered Stapler Associated With Major Reduction In Serious Complications Following Colorectal Surgery
Cinncinnati, OH – Aug. 11, 2021 – Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the results of a new real-world study that shows its ECHELON CIRCULAR Powered Stapler was associated with a 74% reduction in anastomotic leak rates (1.8% vs. 6.9%)[1] and a 44% reduction in 30-day inpatient hospital readmission rates (6.1% vs.10.8%) after colorectal surgery compared with manual circular staplers.[2]The study, published in Surgical Endoscopy, shows the groundbreaking device is just as effective in reducing life-threatening and costly surgical complications in real-world surgical pra...
Source: Johnson and Johnson - August 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson to Participate in Barclays Global Consumer Staples Virtual Conference
New Brunswick, NJ (August 9, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Consumer Staples Virtual Conference on Friday, September 10th. Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer Health will represent the Company in a session scheduled at 9:20 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hours after the live webcast.### (Source: Johnson and Johnson)
Source: Johnson and Johnson - August 9, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

UPTRAVI ® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)
TITUSVILLE, N.J. – July 30, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI® IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI® therapy, as uninterrupted treatment is considered key for individuals with PAH. UPTRAV...
Source: Johnson and Johnson - July 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company ’s COVID-19 Vaccine
NEW BRUNSWICK, N.J., July 28, 2021 -- We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months. The decision is based on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months when refrigerated at temperatures of 36 – 46 degrees Fahrenheit (2 – 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj, where vaccine providers can confirm the latest expiration dates of our vaccine.Evidence has demonstrated that Johnson & Johnson’s si...
Source: Johnson and Johnson - July 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference
New Brunswick, NJ (July 27th, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10th. Joaquin Duato, Vice Chairman of the Executive Committee will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.A webcast replay will be available approximately 48-hours after the live webcast.### (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 27, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news